Fair Value of Financial Instruments - Schedule of Inputs and Valuation Methodologies Used (Details) - Level 3 - Elusys Therapeutics - Discounted cash flow analysis $ in Thousands	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Contingent consideration receivable, related party | Market interest rate
Fair Value of Financial Instruments
Contingent Consideration	0.147
Contingent consideration receivable, related party | Principal amount
Fair Value of Financial Instruments
Contingent Consideration	2,250
Consideration earn-out receivable, related party | Discount rate
Fair Value of Financial Instruments
Contingent Consideration	0.150
Consideration earn-out receivable, related party | Future revenue projections
Fair Value of Financial Instruments
Contingent Consideration	141,400
Consideration earn-out receivable, related party | Minimum earn-out payment rate
Fair Value of Financial Instruments
Contingent Consideration	0.03
Consideration earn-out receivable, related party | Minimum earn-out payment
Fair Value of Financial Instruments
Contingent Consideration	5,000
Revenue earn-out | Discount rate
Fair Value of Financial Instruments
Contingent Consideration		0.245
Revenue earn-out | Future revenue projections
Fair Value of Financial Instruments
Contingent Consideration		325,900
Deferred contract consideration | Discount rate
Fair Value of Financial Instruments
Contingent Consideration		0.155
Deferred contract consideration | Future revenue projections
Fair Value of Financial Instruments
Contingent Consideration		7,600